about
Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery.The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport.Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.Exploring the efficiency of gallic acid-based dendrimers and their block copolymers with PEG as gene carriers.Determinants of release rate of tetanus vaccine from polyester microspheres.Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers.A polymer/oil based nanovaccine as a single-dose immunization approach.The potential of chitosan in ocular drug delivery.Nanomedicines for overcoming biological barriers.Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide VaccinesNanoparticles as carriers for nasal vaccine delivery.The potential of chitosan for the oral administration of peptides.The performance of nanocarriers for transmucosal drug delivery.Glucomannan, a promising polysaccharide for biopharmaceutical purposes.Nanoparticles as protein and gene carriers to mucosal surfaces.Nanoparticles for nasal vaccination.Chitosan nanoparticles for drug delivery to the eye.Chitosan-based nanostructures: a delivery platform for ocular therapeutics.Chitosan-based drug nanocarriers: where do we stand?Vaccine delivery carriers: insights and future perspectives.Nanotherapies for the treatment of ocular diseases.Nanoengineering of vaccines using natural polysaccharides.Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization.New strategies for the microencapsulation of tetanus vaccine.Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.Recent advances in vaccine delivery.Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy.Polyarginine nanocapsules: A versatile nanocarrier with potential in transmucosal drug delivery.Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers.Polyarginine Nanocapsules as a Potential Oral Peptide Delivery Carrier.Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.Lipid-based nanocarriers for oral peptide delivery.Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs.Heparin-engineered mesoporous iron metal-organic framework nanoparticles: toward stealth drug nanocarriers.Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
P50
Q30357505-08FFE24C-339C-412D-A6D7-C52425C7E125Q30988191-A96661EB-1B01-49BC-8224-B591E0B74CA8Q31096180-4848D9A1-2ECB-43FF-96FB-3882F7BFDDE2Q33184422-12F9299B-C040-45DA-B61C-8BC75FD9C6E5Q33196897-ABF6DF8F-6E94-4E65-9530-4DD297D6EE73Q33214432-4CA52D7B-EA56-4F72-8825-641EEB9C29BAQ34340836-2C9EDD68-D2CB-4BA8-927E-E630829C9286Q34343876-0FAB1274-E717-4D36-AD82-3AF2F7BD4443Q34354937-8DD8DD11-8624-422A-8BA3-9652756031B3Q34445765-47EF6BC5-13A6-4563-9DA8-18017CF1C715Q34685874-B3A97396-F855-498E-AC6E-9C523CCF90A4Q35624563-23BB959F-A46E-49C2-8FE7-C620CD7671ACQ35744965-20235F1A-4727-4A00-B240-E151DF811868Q36101913-1F25CCAE-05DC-468F-8134-AD2BD090C7B5Q36124952-A6BB788E-9406-4A83-A870-2B235C64F2BDQ36316822-FBC41E8C-84AE-40ED-8B11-C5ACDB3B1AB0Q36527739-7CB968E3-02A9-426F-938A-96D668AD328EQ37176804-1E94674F-6458-4D80-8C3B-0582B2C28539Q37331802-37118409-C9FD-4BA6-B49C-02B9279CB4B0Q37361736-9BD366F1-C9E8-4CF5-A521-D77EE4E3B704Q37416144-9FC5F9A8-0A6D-4B4E-882C-B8A37D7E2918Q37643883-AA51837E-B24B-4890-AC2D-49227D0B6859Q38000378-721F699E-1284-4B36-BF2B-3E446FAF774EQ38007823-6680B3EF-8609-4E3F-94EA-16B095490A36Q38366039-A620E852-DE2C-4C44-A148-AB8029DFF4EDQ38517950-A3B62695-0695-4A43-BF03-EAD9C77B4ABAQ38550145-31F68268-CBE4-4BE5-861E-A16B5F8C98E5Q38551740-55B6816B-CA4E-4D89-AD13-03FC1950778CQ38603362-0161B542-F8CB-45C3-B41E-9A4F454D9BF9Q38669255-085A8679-A553-4351-8357-4E098020D012Q38671253-A823FE89-B8A1-4F08-BB79-C51A70A88F31Q38697920-5218734C-C14F-43F0-BC5C-22B6D10111AAQ38714992-B4862F68-563E-4B7D-A29B-035675CB0ABEQ38730655-6F4E128E-30F7-4D34-AAA0-4D322C2FEA79Q38752780-8BAC85F3-8A39-4512-88A5-5A6A463888F9Q38782668-00912B90-A217-4F47-B024-6D44A39F50E4Q38808878-8DF51B45-2AA1-4EEC-8B59-AEBC4CD792C8Q38851153-30FED23A-D61B-4BB6-8624-C08554484E14Q38899947-4EDF032C-0D06-4742-A418-62BDCCFD89CEQ38928173-410F7DD4-1420-4836-9123-81B78DE04FB0
P50
description
researcher ORCID: 0000-0001-7187-9567
@en
wetenschapper
@nl
name
María J Alonso
@es
María J Alonso
@nl
María J Alonso
@sl
María J. Alonso
@en
type
label
María J Alonso
@es
María J Alonso
@nl
María J Alonso
@sl
María J. Alonso
@en
prefLabel
María J Alonso
@es
María J Alonso
@nl
María J Alonso
@sl
María J. Alonso
@en
P106
P1153
35073488900
55883024100
P21
P31
P496
0000-0001-7187-9567